TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc-binding domains
✍ Scribed by Professor Anne-Lise Børresen; Tone Ikdahl Andersen; Jorunn E. Eyfjörd; Renee S. Cornelis; Steinunn Thorlacius; Åke Borg; Ulla Johansson; Charles Theillet; Siegfried Scherneck; Susanne Hartman; Cees J. Cornelisse; Eivind Hovig; Peter Devilee
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 406 KB
- Volume
- 14
- Category
- Article
- ISSN
- 1045-2257
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Acquired mutations in TP53 as well as immunohistochemically detectable protein expression have been implicated as prognostic factors for breast cancer. We have evaluated the relationship between mutations detected in 119 breast tumours and various clinicohistopathological indices, stratifying the mutations according to the functional domains as defined by the recent elucidation of the crystal structure of the protein. Patients with missense mutations located in regions encoding parts of the protein involved in zinc‐binding had significantly decreased disease‐free and overall survival relative to patients whose tumours had mutations in other domains. These results indicate that these biochemically defined domains also have biological relevance in terms of breast cancer disease course, and suggest that some mutations in TP53, more than others, can contribute to the development of clinically more aggressive and perhaps treatment resistant breast tumours. When confirmed, this will be of potential importance in predicting the clinical behaviour of breast cancer and its responsiveness to therapy.